Loading clinical trials...
Loading clinical trials...
A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors
Conditions
Interventions
MRx0518
Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Locations
5
United States
University of Kansas Medical Center
Kansas City, Kansas, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Houston Methodist Cancer Center
Houston, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Summit Cancer Center
Spokane, Washington, United States
Start Date
January 10, 2019
Primary Completion Date
May 8, 2023
Completion Date
May 8, 2023
Last Updated
June 1, 2023
NCT07489378
NCT05671510
NCT07181681
NCT06257264
NCT07360314
NCT07204340
Lead Sponsor
4D pharma plc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions